TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19268776

Group type: EXPERIMENTAL
Intervention: Low-dose doxycycline (50 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Medium-dose doxycycline (100 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose doxycycline (300 mg/d)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 60
Study: 17339500

Group type: EXPERIMENTAL
Intervention: Intermittent high-intensity exercise (IHE)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Continuous moderate-intensity exercise (MOD)
Number of subjects: 9
Study: 15081437

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 545

Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 545
Study: 11723438

Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 116

Group type: COMPARATOR
Intervention: Sildenafil alone
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Sildenafil and L-Arginine
Number of subjects: 116
Study: 9623550

Group type: EXPERIMENTAL
Intervention: Iohexol measured by HPLC
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Iohexol analysed by X‐ray fluorescence
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Multiple-point clearances (HPLC and X-ray fluorescence)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Single-sample method for GFR >40 ml/min
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: X-ray fluorescence analysis of low concentrations of iohexol
Number of subjects: 49
Study: 8146789

Group type: EXPERIMENTAL
Intervention: Intravascular laser blood irradiation (ILBI) with helium-neon laser, daily procedures
Number of subjects: 150
Study: 3292719

Group type: EXPERIMENTAL
Intervention: Vancomycin prophylaxis (single prophylactic dose)
Number of subjects: 360

Group type: COMPARATOR
Intervention: No antimicrobial agents (control group)
Number of subjects: 360
Study: 31410598

Group type: EXPERIMENTAL
Intervention: Early specialized palliative care plus standard care
Number of subjects: 297

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 297
Study: 30547766

Group type: EXPERIMENTAL
Intervention: Combination of mirtazapine with SNRI or SSRI antidepressants
Number of subjects: 59

Group type: COMPARATOR
Intervention: SNRI or SSRI therapy alone
Number of subjects: 59
Study: 26121894

Group type: EXPERIMENTAL
Intervention: C-MAC video-laryngoscope
Number of subjects: 90

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 90
Study: 23973689

Group type: EXPERIMENTAL
Intervention: Non-HDL-C values
Number of subjects: 1310440

Group type: COMPARATOR
Intervention: LDL-C levels <70 mg/dl
Number of subjects: 1310440
Study: 20234350

Group type: EXPERIMENTAL
Intervention: Celecoxib 16 mg/kg/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 18251643

Group type: EXPERIMENTAL
Intervention: Putty P15 and bioabsorbable collagen wound dressing material
Number of subjects: 24

Group type: COMPARATOR
Intervention: bioabsorbable collagen wound dressing material only
Number of subjects: 24
Study: 15999217

Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5 mg
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Darifenacin 30 mg
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study: 12442180

Group type: EXPERIMENTAL
Intervention: With tourniquet
Number of subjects: 37

Group type: COMPARATOR
Intervention: Without tourniquet
Number of subjects: 37
Study: 10338170

Group type: COMPARATOR
Intervention: Conventional spinal block (n = 60)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Unilateral spinal block (n = 60)
Number of subjects: 120
Study: 7795833

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 2382

Group type: EXPERIMENTAL
Intervention: Reduced sodium intake
Number of subjects: 2382

Group type: EXPERIMENTAL
Intervention: Combination of weight loss and reduced sodium intake
Number of subjects: 2382

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 2382
Study: 1781272

Group type: EXPERIMENTAL
Intervention: Active anterior computerized rhinomanometry (C.R.) pre- and post-operatively
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Surgical treatment for patients with increased basal and residual TR
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Surgical treatment for patients with increased basal TR but normal residual TR
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aesthetic treatment for patients with normal total basal resistance
Number of subjects: 50
Study: 10252500

Group type: EXPERIMENTAL
Intervention: Patient-education program consisting of six educational seminars involving various health professionals.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified intervention).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-education program.
Number of subjects: 0
Study: 31148401

Group type: EXPERIMENTAL
Intervention: Iron-fortified rice
Number of subjects: 160

Group type: COMPARATOR
Intervention: Ordinary rice
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nutrition education (more than six modules)
Number of subjects: 160
Study: 28485673

Group type: EXPERIMENTAL
Intervention: iPad audiometer app (Audiogram Mobile) using Apple earbud headphones
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2‐channel Type 1 audiometer (GSI‐61) using EAR insert earphones
Number of subjects: 20
Study: 25580924

Group type: EXPERIMENTAL
Intervention: Tetrabenazine (TBZ) 25-150 mg/d for 6 weeks
Number of subjects: 10
Study: 23574533

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day) plus nateglinide (PIO arm)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Glimepiride (2 mg/day) plus placebo (GLI arm)
Number of subjects: 16
Study: 21535435

Group type: EXPERIMENTAL
Intervention: SenseWear™ Pro(2) Armband
Number of subjects: 29

Group type: COMPARATOR
Intervention: Indirect calorimetry
Number of subjects: 29
Study: 20191170

Group type: EXPERIMENTAL
Intervention: Instructions regarding the use of the ABCD rule
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no instructions)
Number of subjects: 80
Study: 17338998

Group type: EXPERIMENTAL
Intervention: Iron sucrose intravenously 200 mg once per week for 5 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate 200 mg by mouth 3 times per day for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15550791

Group type: EXPERIMENTAL
Intervention: Levosimendan low dose (12 microg/kg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Levosimendan high dose (24 microg/kg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 11523755

Group type: EXPERIMENTAL
Intervention: Improvements to social competence
Number of subjects: 0
Study: 11201872

Group type: EXPERIMENTAL
Intervention: Methods to prevent further impairment and subsequent disability (POID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical or occupational therapy, reconstructive surgery, or temporary socioeconomic assistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICIDH-2 framework for rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Studies of methods to improve detection of neuropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trials of alternative drugs or regimens for treating neuropathy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Studies of POID-monitoring systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Studies of instruments to assess limitations of activities and restrictions on participation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Studies of the efficacy of various types of rehabilitation interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Studies of cost-effectiveness of rehabilitation interventions
Number of subjects: 0
Study: 9444707

Group type: EXPERIMENTAL
Intervention: Induced hypotension (mean arterial pressure, MAP, 50‐64 mmHg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normotension (MAP > or = 65 mmHg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Induced hypotension
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normotension
Number of subjects: 36
Study: 1441872

Group type: EXPERIMENTAL
Intervention: 1% prilocaine (20 ml) for 3-in-1 block
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: 30 ml prilocaine for 3-in-1 block
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: 35 ml prilocaine for 3-in-1 block
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Combined sciatic block
Number of subjects: 852
Study: 3515918

Group type: EXPERIMENTAL
Intervention: Flurbiprofen, 100 mg twice daily
Number of subjects: 133

Group type: COMPARATOR
Intervention: Naproxen, 250 mg twice daily
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Flurbiprofen, 100 mg twice daily (open-label phase)
Number of subjects: 133
Study: 30745885

Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg once-weekly (n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 45
Study: 27316586

Group type: EXPERIMENTAL
Intervention: Home-based integrated cardiac rehabilitation (HBICR)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 64
Study: 25321620

Group type: EXPERIMENTAL
Intervention: Nitinol partially covered SEMS
Number of subjects: 400

Group type: COMPARATOR
Intervention: Steel partially covered SEMS
Number of subjects: 400
Study: 22669847

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib with laser therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laser therapy alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group for bevacizumab
Number of subjects: 0
Study: 19728082

Group type: EXPERIMENTAL
Intervention: Fluvastatin high dose (80 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluvastatin low dose (20 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluvastatin (both doses)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fluvastatin (high grade tumors)
Number of subjects: 40
Study: 18515511

Group type: EXPERIMENTAL
Intervention: Nonsuction drain
Number of subjects: 69

Group type: COMPARATOR
Intervention: Suction drain
Number of subjects: 69
Study: 16082323

Group type: EXPERIMENTAL
Intervention: Tacrolimus + Sirolimus
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Tacrolimus + Mycophenolate Mofetil (MMF)
Number of subjects: 361
Study: 11922360

Group type: EXPERIMENTAL
Intervention: Tourniquet on the upper arm
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tourniquet on the forearm
Number of subjects: 50
Study: 10516867

Group type: EXPERIMENTAL
Intervention: Verapamil (5 mg/hour intravenously for the first 24 hours, followed by 120 mg t.i.d. perorally for 6 months)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (equivalent to verapamil)
Number of subjects: 70
Study: 7628095

Group type: EXPERIMENTAL
Intervention: Lecithin/sphingomyelin (L/S) ratios
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Surfactant/albumin (S/A) ratios
Number of subjects: 47
Study: 2038732

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Theophylline (twice a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inhaled terbutaline (1 mg four times a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combination of theophylline and terbutaline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of terbutaline and theophylline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Theophylline alone
Number of subjects: 30
Study: 30573851

Group type: EXPERIMENTAL
Intervention: Permissive Underfeeding
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard Feeding
Number of subjects: 50
Study: 27189615

Group type: EXPERIMENTAL
Intervention: Cryotherapy made with chamomile infusion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cryotherapy made only with water (control group)
Number of subjects: 38
Study: 24666884

Group type: EXPERIMENTAL
Intervention: tolterodine/pilocarpine (2/9 mg)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: tolterodine IR 2 mg
Number of subjects: 138

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: tolterodine/pilocarpine (3/13.5 mg)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: tolterodine extended-release 4 mg
Number of subjects: 138
Study: 21963581

Group type: EXPERIMENTAL
Intervention: Insulin multifaceted safety program
Number of subjects: 2117

Group type: EXPERIMENTAL
Intervention: Accidental tube/catheter removal multifaceted safety program
Number of subjects: 2117

Group type: EXPERIMENTAL
Intervention: Anticoagulation multifaceted safety program
Number of subjects: 2117

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2117
Study: 20234126

Group type: EXPERIMENTAL
Intervention: >2 h of physical activity per week
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Self-reported health status as fair or poor
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Total lung capacity (every 10% increase)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Self-reported anxiety
Number of subjects: 597
Study: 18629370

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (an angiotensin II type 1 receptor blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (standard therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0
Study: 16020522

Group type: EXPERIMENTAL
Intervention: Exercise training over 12 weeks in lung transplant recipients (LR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Exercise training over 12 weeks in male controls (C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Baseline measurements in lung transplant recipients (LR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Post-training measurements in lung transplant recipients (LR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Post-training measurements in male controls (C)
Number of subjects: 24
Study: 12900341

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) 0.625 mg/d for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) 0.3125 mg/d for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 11036894

Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 457

Group type: COMPARATOR
Intervention: Stroke team
Number of subjects: 457

Group type: COMPARATOR
Intervention: Domiciliary care
Number of subjects: 457
Study: 9833023

Group type: EXPERIMENTAL
Intervention: Non-EKG-triggered lithotripsy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Triggered lithotripsy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Non-EKG-triggering lithotripsy
Number of subjects: 25
Study: 1281259

Group type: EXPERIMENTAL
Intervention: GHRH + porcine galanin (12.5 micrograms/min in 100 mL saline)
Number of subjects: 12

Group type: COMPARATOR
Intervention: GHRH + saline (100 mL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GHRH + galanin infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: GHRH
Number of subjects: 12
Study: 6744948

Group type: EXPERIMENTAL
Intervention: Econazole nitrate 1.0 percent cream once a day
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 126
Study: 31731677

Group type: EXPERIMENTAL
Intervention: Health-related product information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environmental-friendliness-related product information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of health and environmental messages
Number of subjects: 0
Study: 28826166

Group type: EXPERIMENTAL
Intervention: Myofascial trigger therapy (MT) combined with Cellconnect Impulse vibrotreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Myofascial trigger therapy (MT)
Number of subjects: 0
Study: 26650913

Group type: EXPERIMENTAL
Intervention: Thin strut bare metal stenting in AF patients
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Thin strut bare metal stenting in non-AF patients
Number of subjects: 783
Study: 25317087

Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) of 40 mm Hg for 20 minutes
Number of subjects: 24
Study: 22715372

Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg/day
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 20651475

Group type: EXPERIMENTAL
Intervention: Simulation instruction
Number of subjects: 83

Group type: COMPARATOR
Intervention: Group discussion
Number of subjects: 83
Study: 17106839

Group type: EXPERIMENTAL
Intervention: Acute psychiatric day-hospital treatment
Number of subjects: 191

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 191
Study: 16381143

Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 12214339

Group type: EXPERIMENTAL
Intervention: UDCA (15 mg/kg day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study: 9790157

Group type: EXPERIMENTAL
Intervention: Citalopram (20+/−10 mg/day) during luteal phase only and placebo during follicular phase (intermittent treatment)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Citalopram continuously at a constant dosage (20+/−10 mg/day) throughout the menstrual cycle (continuous treatment)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Citalopram continuously throughout the cycle at a lower dosage in the follicular phases (5 mg/day) than in the luteal phases (20+/−10 mg/day) (semi-intermittent treatment)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo throughout the cycles
Number of subjects: 69
Study: 7615287

Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (n = 11)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No therapy (n = 10)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Symptomatic treatment (n = 13)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: No previous bacteriologically proved urinary tract infection (n = 24)
Number of subjects: 58
Study: 2236690

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) for diagnosing active inflammatory bowel disease (IBD)
Number of subjects: 61
Study: 877819

Group type: EXPERIMENTAL
Intervention: Topical antibiotic povidone-iodine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teflon catheters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Steel needles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine venipuncture inspections every eight hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion site examination every eight hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion duration
Number of subjects: 0
Study: 31644921

Group type: EXPERIMENTAL
Intervention: Community-based behavioral lifestyle intervention program (24 months)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 480
Study: 28452404

Group type: EXPERIMENTAL
Intervention: Antenatal lifestyle intervention
Number of subjects: 1867

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1867
Study: 25527487

Group type: EXPERIMENTAL
Intervention: HABIT‐ILE (10 days = 90 hours)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HABIT‐ILE
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 24
Study: 23640589

Group type: COMPARATOR
Intervention: 70 ml concentrated beetroot juice (BR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 140 ml concentrated beetroot juice (BR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 280 ml concentrated beetroot juice (BR)
Number of subjects: 10
Study: 21482029

Group type: EXPERIMENTAL
Intervention: Sleep disturbances at baseline
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Sleep disturbances at 1 month post-quit
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Drowsiness, insomnia, and sleep quality changes over time
Number of subjects: 322
Study: 2704174

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, 70 mg/d for 4 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 16631668

Group type: EXPERIMENTAL
Intervention: Multimedia course
Number of subjects: 126

Group type: COMPARATOR
Intervention: Print version
Number of subjects: 126
Study: 12072597

Group type: EXPERIMENTAL
Intervention: Endoscopic Papillary Balloon Dilation (EPBD)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (EST)
Number of subjects: 140
Study: 10483698

Group type: EXPERIMENTAL
Intervention: Indian version (maternal positioning exercise)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Comparison group (spontaneous version)
Number of subjects: 109
Study: 9772612

Group type: EXPERIMENTAL
Intervention: Niaodujing (NDJ) treatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (aldehyde coated oxystarch)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Comparison between NDJ and control group
Number of subjects: 105
Study: 1656827

Group type: EXPERIMENTAL
Intervention: Combined modality therapy (MACC: intravenous methotrexate, intravenous doxorubicin, intravenous cyclophosphamide, and oral lomustine) followed by thoracic radiotherapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Thoracic radiation therapy alone (5000 cGy in 5 weeks with a 1000 cGy boost)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 121

Group type: COMPARATOR
Intervention: Thoracic radiation only
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 121
Study: 6408808

Group type: EXPERIMENTAL
Intervention: sulfinpyrazone (Anturan) 800 mg/die
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 31381152

Group type: EXPERIMENTAL
Intervention: fosnetupitant 81 mg
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: fosnetupitant 235 mg
Number of subjects: 594

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 594